International lack of equity in modern obesity therapy: the critical need for change in health policy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Network SDS Indicators and a Monitoring Framework Launching a data revolution for the Sustainable Development Goals. Available from: https://indicators.report/targets/3-4/ . Hecker J, Freijer K, Hiligsmann M, Evers SMAA. Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. BMC Public Health. 2022;22:46. Article CAS Google Scholar Nielsen HJ, Nedrebø BG, Fosså A, Andersen JR, Assmus J, Dagsland VH, et al. Seven-year trajectories of body weight, quality of life and comorbidities following Roux-en-Y gastric bypass and sleeve gastrectomy. Int J Obesity. 2022;46:739–49. Article CAS Google Scholar Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: A comparison of prescribing patterns of anti-obesity pharmacotherapies and SGLT2s. Obesity. 2016;24:1955–61. Article Google Scholar Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–61. Agency EM Wegovy 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy . Gomez G, Stanford FCUS. health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes. 2018;42:495–500. Article CAS Google Scholar Justice TFMo. Social Code Book V - Statutory Health Insurance - (Article 1 of the Act of December 20, 1988, BGBl. I S. 2477) § 34 Excluded drugs, remedies and aids. Available from: https://www.gesetze-im.internet.de/sgb_5/__34.html . Wenar L John RawlsSummer 2021. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017;7:e014287. Article Google Scholar Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010;34 Suppl 1 (0 1)):S47–55. Kolata G The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ The New York Times 2022. Available from: https://www.nytimes.com/2022/05/31/health/obesity-drugs.insurance.html?referringSource=articleShare . All countries significantly off track to meet 2025 WHO targets on Obesity [press release]. World Obesity Federation 2020. Download references
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, liraglutide prices are more than 50% higher in the United States when prescribed for the indication of antiobesity treatment compared with when prescribed for its antidiabetic effects, adding to stigma around obesity and demonstrating pricing injustice [13].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, semaglutide (Ozempic and Wegovy, the exact same subcutaneous medication) costs threefold as much in Australia, and 50% more in America, if prescribed for obesity rather than diabetes”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Disparities exist in the regulatory approval and availability of OMMs across different countries64–66.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [65]
The cited source says what the claim attributes to it.
In the citing paper
“Access to semaglutide 2.4 mg emerged as a significant barrier for many users, with shortages [10] and insurance coverage issues hindering medication availability and equity [9].”
From A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss (2025) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adaptive thermogenesis in humans
Rosenbaum, M., & Leibel, R. L. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.184 · Cited by 349 · cited 1×
“Indeed, lifestyle interventions alone are often ineffective for patients with obesity because the biological response to restoring weight to the highest-sustained level becomes more robust as weight loss increases [11].”
BackgroundSemaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
Hecker, J., Freijer, K., Hiligsmann, M., & Evers, S. M. A. A. (2022) · BMC Public Health · doi:10.1186/s12889-021-12449-2 · Cited by 136
Gomez, G., & Stanford, F. C. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.287 · Cited by 128
Self-citationThomas, C. E., Mauer, E. A., Shukla, A. P., Rathi, S., & Aronne, L. J. (2016) · Obesity · doi:10.1002/oby.21533 · Cited by 124
Morgan, S. G., & Lee, A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014287 · Cited by 112
Nielsen, H. J., Nedrebø, B. G., Fosså, A., Andersen, J. R., Assmus, J., Dagsland, V. H., Dankel, S. N., Gudbrandsen, O. A., Fernø, J., Hjellestad, I., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01028-5 · Cited by 63
Research works printed but not linked: 1
- All countries significantly off track to meet 2025 WHO targets on Obesity [press release]. World Obesity Federation 2020.
Cited by
Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00355-1 · Cited by 1,151
“90 With the rapid increase in the prevalence of overweight and obesity forecasted in many LMICs, it is imperative to ensure proper integration of monitoring and evaluation strategies alongside the introduction of new policies and programmes to accumulate evidence to support continuous policy planning and reform.”
InfluentialHay, S. I., Ong, K. L., Santomauro, D. F., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abate, B. B., Abbafati, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01637-x · Cited by 916
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
Michos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 90
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69
“and 50% more in America, if prescribed for obesity rather than diabetes, which is furthermore unjust and stigmatizing to people living with obesity [13].”
Background
Metadata
- Authors
- Roser, P., Bajaj, S. S., & Stanford, F. C.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Harvard University (US)
- Corresponding author
- Roser, Pia
- Venue
- International Journal of Obesity
- Published
- 2022-07-01
- Volume
- 46
- Issue
- 9
- Pages
- 1571-1572
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC9395261
- OpenAlex
- W4283763285
- Semantic Scholar
- accdd4e15d1a90f5e77c744dc8090307fe7e05c1
- Cited by
- 34
- References
- 7
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 6 · 2023: 8
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (L30 DK118710, DK040561, NIDDK P30 DK040561)
- National Institute of Diabetes and Digestive and Kidney Diseases (L30 DK118710, DK040561, P30DK040561)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity and Health Practices
- Keywords
- obesity treatment, health equity, anti-obesity drugs, prescription drug coverage, health policy, cost-related nonadherence, social determinants of health, semaglutide, Wegovy, bariatric surgery, obesity pharmacotherapy, Sustainable Development Goals, social justice in health care, Germany, United States
- MeSH terms
- Health Policy, Humans, Obesity, Health Status Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International lack of equity in modern obesity therapy: the critical need for change in health policy. https://app.cochat.ai/papers/10.1038/s41366-022-01176-2
- The paper
- Roser, P., Bajaj, S. S., & Stanford, F. C. (2022). International lack of equity in modern obesity therapy: the critical need for change in health policy. International Journal of Obesity. https://doi.org/10.1038/s41366-022-01176-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.